GSK3B and schizophrenia: The immunodensity of GSK3β was found unaltered in schizophrenia (C: 122% ± 8%; SZ: 119% ± 10%) (Figure 1D), and the antipsychotic treatment did not modify significantly the content of the protein (AP-F: 134% ± 14%; AP-T: 100% ± 12%).